PEGASYS

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Liver TransplantChronic Hepatitis

95 competitors in Liver Transplant

#DrugCompanyPhaseTrials

1

PEGASYS

Ppharmaand GmbH

Approved

12

Prothrombin Complex Concentrate

CSL Behring

Phase 3

13

Darbepoetin

Bayer

Phase 3

14

Tacrolimus Pill

EEdward Geissler

Phase 3

15

Lenvima

Eisai

Preclinical

26

Octreotide

Johnson & Johnson

Preclinical

27

Beyfortus

BeiGene

Preclinical

18

Prostigmin

Merck & Co.

Preclinical

19

Myfortic

Novartis

Preclinical

110

Cyklokapron

JJ Molner

Preclinical

2Show 33 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Chronic Hepatitis24 trials

REP 2139-Mg and REP 2165-Mg Combination Therapy in Chronic Hepatitis B Infection

Completed·RReplicor Inc.·Phase 2·NCT02565719·40 enrolled

A Study of RO5190591 (Danoprevir) in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Genotype 1 Virus Infection

Completed·Roche·Phase 2·NCT00963885·229 enrolled

Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase Ib Study in Chronic Hepatitis B Patients

Completed·BBeijing Bio-Fortune Ltd.·Phase 1/2·NCT01997944·32 enrolled

Show 21 more trials

A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed·Gilead·Phase 2·NCT01271790·245 enrolled

Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)

Unknown status·Hanmi Pharmaceutical Company Limited·Phase 1/2·NCT02057887·64 enrolled

An Open-label Comparative Efficacy and Safety Study of Algeron (Cepeginterferon Alfa-2b) in Treatment-naive Patients With Chronic Hepatitis C

Completed·BBiocad·Phase 3·NCT01889433·170 enrolled

Efficacy and Safety Study of Peginterferon Alfa-2b in Chinese Chronic Hepatitis C Patients

Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 3·NCT01581398·770 enrolled

A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4

Completed·Roche·Phase 2·NCT00869661·413 enrolled

Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B

Completed·Roche·Phase 3·NCT00048945·820 enrolled

A Study of Response-Guided Duration of Combination Therapy With GS-9190, GS-9256, Pegasys® and Copegus® in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

Completed·Gilead·Phase 2·NCT01225380·324 enrolled

A Study of NeoRecormon (Epoetin Beta) in Anemic Patients With Chronic Hepatitis C.

Completed·Roche·Phase 4·NCT00560274·190 enrolled

Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects

Terminated·Novartis·Phase 1/2·NCT00964665·141 enrolled

Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B

Completed·XXiamen Amoytop Biotech Co., Ltd.·Phase 3·NCT01760122·820 enrolled

A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C

Completed·Roche·Phase 2·NCT01482403·58 enrolled

A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450)

Terminated·Merck & Co.·Phase 3·NCT01641926·402 enrolled

Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B

Completed·AAssembly Biosciences·Phase 1/2·NCT03109730·38 enrolled

Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)

Completed·Merck & Co.·Phase 3·NCT00081770·4,469 enrolled

Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA

Completed·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 3·NCT01892241·74 enrolled

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Completed·Roche·Phase 2·NCT00442572·21 enrolled

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.

Completed·Roche·Phase 2·NCT00517439·516 enrolled

Trial of Pegasys® in Patients With Chronic Hepatitis C

Completed·Roche·Phase 4·NCT00245414·108 enrolled

A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C

Completed·Roche·Phase 2·NCT01331850·381 enrolled

A Study in Healthy Volunteers and Patients With Chronic Hepatitis B

Completed·AAssembly Biosciences·Phase 1·NCT02908191·86 enrolled

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

Completed·Roche·Phase 2·NCT00377182·107 enrolled

Essential Thrombocythemia3 trials

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

Completed·RRonald Hoffman·Phase 3·NCT01259856·168 enrolled

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

Completed·RRonald Hoffman·Phase 2·NCT01259817·135 enrolled

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Completed·JJohn Mascarenhas·Phase 1·NCT02407080·13 enrolled

Hepatitis B2 trials

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Hepatitis B Patient

Completed·TTianjin SinoBiotech Ltd.·Phase 1/2·NCT03294798·11 enrolled

Safety and Efficacy Study of NVR 3-778 in Healthy Volunteers and Hepatitis B Patients

Completed·NNovira Therapeutics, Inc.·Phase 1·NCT02112799·55 enrolled

Safety and Efficacy1 trial

Therapeutic Safety and Efficacy of REP 2139 (REP 9AC') in HBV Infected Patients

Completed·RReplicor Inc.·Phase 1/2·NCT02646189·12 enrolled

Liver Transplant1 trial

Safety and Effectiveness Using Pegasys and Copegus in Recipients of Liver Transplantation With Hepatitis C

Completed·MMayo Clinic·Phase 4·NCT00275548·12 enrolled

10 more indications

Adult Subject1 trial

Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects

Completed·Hanmi Pharmaceutical Company Limited·Phase 1·NCT01504581·48 enrolled

Myeloid Neoplasm1 trial

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms

Completed·TThomas Stauffer Larsen·Phase 3·NCT01387763·202 enrolled

Efficacy1 trial

Dose-Ranging Study to Assess the Safety, PK and Initial Antiviral Efficacy of NVR 3-778 in Chronic HBV Patients

Completed·NNovira Therapeutics, Inc.·Phase 1·NCT02401737·58 enrolled

Immune Suppression1 trial

Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression

Unknown status·ZZealand University Hospital·Phase 2·NCT04798612·68 enrolled

Absorption1 trial

A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants

Terminated·Bristol-Myers Squibb·Phase 1·NCT06144697·267 enrolled

Hepatitis C1 trial

Study of SCY-635, Pegasys and Copegus in Hepatitis C

Completed·SScynexis, Inc.·Phase 2·NCT01265511·10 enrolled

Single Dose1 trial

Single Dose Escalation Study of P1101 in Healthy Adult Male Subjects

Completed·PPharmaEssentia·Phase 1·NCT05129644·48 enrolled

Tolerance1 trial

Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2/3·NCT00391638·56 enrolled

Chronic Hepatitis C Virus Infection1 trial

A Study of Danoprevir Boosted With Low Dose Ritonavir in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C Virus Infection

Completed·Roche·Phase 2·NCT01220947·421 enrolled

Tics1 trial

Comparative Pharmacokinetics and Pharmacodynamics of Peginterferon BIP48 and 40kDa in Healthy Volunteers

Completed·TThe Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)·Phase 1·NCT01889849·32 enrolled

Regulatory

FDA Approval Timeline[4]

Details

Drug Info

Related News